POSITIVELY AWARE 2015 HCV Drug Chart

Page 1

THE POSITIVELY AWARE 2015

HEPATITIS C POSITIVELY AWARE

DRUG CHART

Each drug is recommended for use in combination with other HCV drugs (except Harvoni and Viekira Pak). See drug page or package insert for complete information on dosage requirements. Drug chart information is current as of June 10, 2015. To review the complete POSITIVELY AWARE 2015 HCV Drug Guide online, go to positivelyaware.com.

Harvoni ledipasvir/sofosbuvir, or LDV/SOF

One ledipasvir 90 mg/sofobuvir 400 mg tablet once daily, with or without food.

GENOTYPE (OFF-LABEL USE IN GT4.) FDA APPROVED FOR MONO-INFECTION. OFF-LABEL USE POSSIBLE FOR HIV/HCV CO-INFECTION.

Sovaldi sofosbuvir, SOF, or SOV

One 400 mg tablet once daily, with or without food.

➊➋➌➍➎➏

GENOTYPE FDA APPROVED FOR HIV/HCV CO-INFECTION.

Viekira Pak ombitasvir/paritaprevir/ritonavir and dasabuvir, or OMB/PTV-R + DAS

Two ombitasvir 12.5 mg/paritaprevir 75 mg/ritonavir 50 mg tablets once daily and one dasabuvir 250 mg tablet twice daily, with a meal. GENOTYPE ➊ (OFF-LABEL USE IN GT4.) FDA APPROVED FOR HIV/HCV CO-INFECTION.

Olysio simeprevir, or SMV

One 150 mg capsule once daily, with food. Do not crush or dissolve the capsule.

GENOTYPE FDA APPROVED FOR MONO-INFECTION. OFF-LABEL USE MAY OCCUR FOR HIV/HCV CO-INFECTION.

Copegus; Rebetol; Ribasphere ribavirin, or RBV

Ribavirin dosage depends upon the brand, and is given in either fixed doses or in doses related to weight (weight-based). The dose range is 800 mg to 1,400 mg per day taken in two divided doses. Depending upon the manufacturer, tablets are available in 200 mg, 400 mg, 500 mg, and 600 mg. A liquid dose is also available. Must be taken with food.

➊➋➌➍➎➏

GENOTYPE FDA APPROVED FOR HIV/HCV CO-INFECTION.

PegIntron; Pegasys peginterferon alfa-2b; peginterferon alfa-2a or rPEG; PEG IFN; IFN; pegylated interferon; interferon

Administer one injection once a week with or without food; must be taken in combination with ribavirin and other HCV drugs. Interferon should never be taken by itself.

➊➋➌➍➎➏

GENOTYPE FDA APPROVED FOR HIV/HCV CO-INFECTION.

daclatasvir, or DCV NOT YET APPROVED. Take one 60 mg tablet once daily with or without food; 30 mg tablets are sold in Europe and may be available in U.S. upon approval.

➊➌➍

GENOTYPE LIKELY TO BE APPROVED FOR HIV/HCV CO-INFECTION.

grazoprevir/elbasvir, or GZR/EBR formerly MK-5172, MK-8742

NOT YET APPROVED. Studied as a fixed-dose combination of grazoprevir 100 mg/elbasvir 50 mg. GENOTYPE LIKELY TO BE APPROVED FOR HIV/HCV CO-INFECTION.

➊➍➏


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.